Klaus Klumpp PhD

Klaus Klumpp, Ph.D., is a co-founder of Riboscience, LLC, a biotech spin-off from Roche developing ribose-derived molecules for the treatment of infectious diseases and cancer. As vice president, discovery research, at Novira Therapeutics Inc. from 2013-2016 he established biology research operations for Novira and supported the progression of a novel treatment of HBV infection into clinical safety and efficacy trials, which drove the acquisition of Novira by Johnson & Johnson. Before that, he led research and development activities in the viral disease area at Roche for 15 years rising to the level of vice president and global head of virology discovery.

Klaus was a Research performed under his direction at Roche has supported clinical development of antiviral drugs such as Tamiflu for the treatment and prophylaxis of influenza virus infection, and Balapiravir, Mericitabine, and Danoprevir, new antiviral agents for the treatment of hepatitis C virus (HCV) infection. His work resulted in the discovery of a number of drug candidates for the treatment of acute and chronic viral diseases including influenza, Hepatitis C, Hepatitis B, Dengue, and HIV. As an advisor of Viriom Inc., he supported the candidate selection and its successful progression through clinical development to become Elpida, a novel treatment of HIV infection. As an advisor of Savira Pharmaceuticals GmbH, he guided company strategy adjustment and crystal structure assisted lead optimization of drug candidates for the treatment of influenza, resulting in a licensing agreement with Roche in 2017. He has also held research fellow positions at GlaxoWellcome Research and Development and the European Molecular Biology Laboratory (EMBL) institutes.